Ethris GmbH
http://www.ethris.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ethris GmbH
India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023
India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. In Vivo's sister publication Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023.
Cipla's Advair Generic Debut Is In Sight
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.
Cipla's Advair Generic Debut In Sight, More Platform Deals On Radar Post Ethris
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.
India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023
India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice